^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    N201

    i
    Other names: N201, TC-N201, NY-ESO-1 TCR
    Associations

    News

    Trials
    Company:
    TCRCure
    Drug class:
    TCR modulator, NY ESO 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (clinicaltrials.gov)
    P1/2, N=600, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1/2 trial • IO biomarker
    |
    izalontamab brengitecan (BL-B01D1) • MT027 • N201 • YSCH-01 • tirbanibulin oral (KX-01 oral)
    7ms
    NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, TCRCure Biopharma Ltd. | Trial completion date: Mar 2025 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201
    almost2years
    NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, TCRCure Biopharma Ltd. | Phase classification: P1/2 --> P1 | Trial primary completion date: Oct 2023 --> Oct 2024
    Phase classification • Trial primary completion date • Metastases
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    CTAG1B expression
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201
    over2years
    NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=18, Recruiting, TCRCure Biopharma Ltd.
    New P1/2 trial • Metastases
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    CTAG1B expression
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201